Radiation schedule study for Merkel cell skin cancer
Part of Cancer, Infections clinical trials.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your doctor) have confirmed Merkel cell carcinoma (MCC) from a biopsy or other test.
- There is no evidence the cancer has spread to distant organs on exam and imaging scans.
- You must be at least 18 years old.
- Your planned treatment is either radiation to the primary tumor after surgery within 4 months, or radiation to lymph nodes after specific lymph node surgery/testing within 4 months.
- You cannot be currently pregnant, and you must use effective birth control during the study (and for men, also for 6 months after radiation ends).
- You should be well enough to do daily activities (ECOG score 0 to 3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
This trial tests a new combination for people with advanced Merkel cell carcinoma (MCC), a rare skin cancer. It combines the immunotherapy drug pembrolizumab with standard chemotherapy (cisplatin or carboplatin plus etoposide). The goal is to see if this combination shrinks or controls the cancer better than chemotherapy alone.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This study tests a combination of two medicines—an oral therapy (ASTX727) and an immunotherapy (retifanlimab)—for people with advanced Merkel cell carcinoma that has not responded to prior immunotherapy. The goal is to see if this new combination can help shrink or control the cancer.
This study looks at how people with Merkel cell carcinoma, a rare skin cancer, take part in clinical trials. By joining, you help researchers understand how to make trials easier for patients like you.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.